PL2295035T3 - Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep) - Google Patents

Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep)

Info

Publication number
PL2295035T3
PL2295035T3 PL10173506.6T PL10173506T PL2295035T3 PL 2295035 T3 PL2295035 T3 PL 2295035T3 PL 10173506 T PL10173506 T PL 10173506T PL 2295035 T3 PL2295035 T3 PL 2295035T3
Authority
PL
Poland
Prior art keywords
superstructures
arb
nep
blocker
inhibitor
Prior art date
Application number
PL10173506.6T
Other languages
English (en)
Inventor
Suliman Al-Fayoumi
Jiahui Hu
Natrajan Kumaraperumal
Alan Edward Royce
Colleen Ruegger
Erika Aina Zannou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2295035(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2295035T3 publication Critical patent/PL2295035T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10173506.6T 2007-11-06 2008-11-04 Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep) PL2295035T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98566807P 2007-11-06 2007-11-06

Publications (1)

Publication Number Publication Date
PL2295035T3 true PL2295035T3 (pl) 2016-11-30

Family

ID=40451030

Family Applications (3)

Application Number Title Priority Date Filing Date
PL08848154T PL2217205T3 (pl) 2007-11-06 2008-11-04 Zastosowanie blokera receptora angiotensyny (ARB) oraz inhibitora obojętnej endopeptydazy (NEP) jako składników farmaceutycznych w leczeniu choroby nadciśnieniowej
PL16157767.1T PL3067043T3 (pl) 2007-11-06 2008-11-04 Kompozycje farmaceutyczne oparte na superstrukturach antagonisty/blokera receptora angiotensyny (arb) i inhibitora obojętnej endopeptydazy (nep)
PL10173506.6T PL2295035T3 (pl) 2007-11-06 2008-11-04 Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL08848154T PL2217205T3 (pl) 2007-11-06 2008-11-04 Zastosowanie blokera receptora angiotensyny (ARB) oraz inhibitora obojętnej endopeptydazy (NEP) jako składników farmaceutycznych w leczeniu choroby nadciśnieniowej
PL16157767.1T PL3067043T3 (pl) 2007-11-06 2008-11-04 Kompozycje farmaceutyczne oparte na superstrukturach antagonisty/blokera receptora angiotensyny (arb) i inhibitora obojętnej endopeptydazy (nep)

Country Status (33)

Country Link
US (3) US20100267786A1 (pl)
EP (4) EP2295035B1 (pl)
JP (2) JP5653218B2 (pl)
KR (2) KR101589317B1 (pl)
CN (2) CN103251587A (pl)
AR (1) AR069184A1 (pl)
AU (1) AU2008324878B2 (pl)
BR (1) BRPI0823505A2 (pl)
CA (1) CA2703598C (pl)
CL (1) CL2008003298A1 (pl)
CY (2) CY1116280T1 (pl)
DK (3) DK2217205T3 (pl)
EC (1) ECSP10010160A (pl)
ES (3) ES2536514T3 (pl)
FI (1) FI3067043T3 (pl)
GT (1) GT201000131A (pl)
HR (3) HRP20150459T1 (pl)
HU (2) HUE028866T2 (pl)
IL (3) IL262990B2 (pl)
JO (1) JOP20080499B1 (pl)
MA (1) MA31797B1 (pl)
MX (1) MX2010004930A (pl)
MY (1) MY153730A (pl)
NZ (1) NZ584686A (pl)
PE (2) PE20141072A1 (pl)
PL (3) PL2217205T3 (pl)
PT (3) PT2295035T (pl)
RU (1) RU2493844C3 (pl)
SG (1) SG185951A1 (pl)
SI (3) SI2217205T1 (pl)
TN (1) TN2010000200A1 (pl)
TW (1) TWI484982B (pl)
WO (1) WO2009061713A1 (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536514T3 (es) 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)
CA2763572C (en) 2009-05-28 2017-10-17 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
MA33364B1 (fr) 2009-05-28 2012-06-01 Novartis Ag Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2702529T3 (es) * 2010-08-24 2019-03-01 Novartis Ag Una composición farmacéutica para uso en la prevención o tratamiento de la insuficiencia cardíaca en un mamífero que recibe terapia anticoagulante
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
SI2887961T1 (sl) * 2012-08-24 2021-08-31 Novartis Ag Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju
WO2014126979A1 (en) 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
AU2014216417B2 (en) 2013-02-14 2016-05-12 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
SI4321157T1 (sl) 2013-08-26 2025-03-31 Novartis Ag Nova uporaba kombinacije blokatorja receptorja angiotenzina (arb) z nevtralnim zaviralcem endopeptidaze (nepi)
JP2016530282A (ja) * 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
WO2015154673A1 (en) * 2014-04-10 2015-10-15 Zhaoyin Wang Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
CN110938042B (zh) 2014-12-08 2022-12-13 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
CN104473938B (zh) * 2014-12-30 2017-06-09 北京瑞都医药科技有限公司 一种治疗慢性心衰药物及其制备方法
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
RS64242B1 (sr) 2015-05-11 2023-06-30 Novartis Ag Režim doziranja sakubitril-valsartana za lečenje srčane insuficijencije
EP3302460A1 (en) 2015-05-29 2018-04-11 Novartis AG Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN106176724A (zh) * 2015-07-11 2016-12-07 凌莉 一种稳定的固体药物组合物及其制备方法
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN106074421A (zh) * 2015-07-11 2016-11-09 凌莉 一种提高稳定性的药物组合物
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
CN106176725A (zh) * 2015-07-11 2016-12-07 凌莉 一种提高稳定性的药物组合物及其制备方法和用途
CN106176723A (zh) * 2015-07-11 2016-12-07 凌莉 一种固体药物组合物及其制备方法
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106397248A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种lcz696结晶粉末及其制备方法
US10596151B2 (en) 2015-08-28 2020-03-24 Novartis Ag Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
WO2017037596A1 (en) * 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of lcz-696
CN106580908A (zh) * 2015-10-16 2017-04-26 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (en) * 2015-11-20 2017-05-26 Lupin Limited Amorphous sacubitril-valsartan complex and process for preparation thereof
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CN105935358B (zh) * 2015-12-18 2019-06-07 重庆两江药物研发中心有限公司 一种沙库比曲缬沙坦缓释剂及其制备方法
CN105929031B (zh) * 2015-12-18 2018-08-21 重庆两江药物研发中心有限公司 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
EP4609912A3 (en) * 2016-02-03 2025-11-12 Novartis AG New use of a combination of sacubitril and valsartan
HK1256865A1 (zh) * 2016-02-03 2019-10-04 Novartis Ag 有机化合物的盖伦制剂
CN105748420B (zh) * 2016-03-04 2018-11-06 山东省药学科学院 一种治疗心力衰竭的lcz696缓释骨架片的制备方法
CN105902506A (zh) * 2016-06-12 2016-08-31 佛山市腾瑞医药科技有限公司 一种沙卡布曲缬沙坦制剂及其应用
WO2018069937A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof
EP3600255B1 (en) * 2017-03-31 2021-07-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Stable hot-melt extrudate containing valsartan and sacubitril
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2018211479A1 (en) 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
MX391562B (es) 2017-07-28 2025-03-21 Synthon Bv Composicion farmaceutica que comprende sacubitril y valsartan
US20200276129A1 (en) 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
WO2019180735A1 (en) * 2018-03-19 2019-09-26 Natco Pharma Limited Stable pharmaceutical compositions comprising sacubitril-valsartan complex
US11877576B2 (en) 2018-06-22 2024-01-23 Ideaz, Llc Diphenyl tablets and methods of preparing the same
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
KR102545274B1 (ko) 2020-02-26 2023-06-20 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20210138510A (ko) 2020-05-12 2021-11-19 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko) 2021-01-20 2023-01-10 주식회사 대웅제약 Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US607355A (en) 1898-07-12 Carrier for bicycles
US607893A (en) 1898-07-26 Automatic switch-operating machine
US608220A (en) 1898-08-02 Mechanical movement
US735093A (en) 1903-01-31 1903-08-04 Oscar Greenwald Elevator-cable guard.
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
CN1285739A (zh) * 1997-11-17 2001-02-28 史密丝克莱恩比彻姆公司 高药物负荷立即和改性释放口服制剂和它们的生产方法
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
JP4588877B2 (ja) * 1998-06-17 2010-12-01 ブリストル−マイヤーズ スクイブ カンパニー Ａｄｐ−受容体抗血小板物質と抗高血圧薬の組合せ投与による脳梗塞の予防
TR200805275T2 (tr) * 1998-12-23 2008-09-22 Novartis Ag AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
IL153882A0 (en) 2000-07-19 2003-07-31 Novartis Ag Valsartan salts
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
EP1467728B1 (en) 2002-01-17 2007-08-22 Novartis AG Pharmaceutical compositions comprising valsartan and nep inhibitors
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
AU2003223637A1 (en) 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2004083192A1 (en) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd. Polymorphis of valsartan
WO2005014043A1 (en) 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
US20090304755A1 (en) * 2005-10-27 2009-12-10 Raghu Rami Reddy Kasu Pharmaceutical formulation of losartan
US20080227836A1 (en) 2005-10-31 2008-09-18 Lupin Ltd Stable Solid Oral Dosage Forms of Valsartan
DK1951111T3 (da) 2005-11-07 2010-11-22 Stryker Corp Patienthåndteringsanordning med visning af lokal status, one-touch fowler-vinkelindstilling og aktiveringsalarmopsætning
RU2008122712A (ru) 2005-11-08 2009-12-20 Новартис АГ (CH) Комбинация органических соединений
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
ES2536514T3 (es) 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)

Also Published As

Publication number Publication date
HRP20160988T1 (hr) 2016-10-07
PT3067043T (pt) 2023-03-01
ES2536514T3 (es) 2015-05-26
EP3067043B1 (en) 2022-11-30
CN103251587A (zh) 2013-08-21
AU2008324878B2 (en) 2013-04-18
GT201000131A (es) 2012-04-30
JOP20080499B1 (ar) 2022-09-15
TW200936183A (en) 2009-09-01
KR20150139624A (ko) 2015-12-11
HUE061321T2 (hu) 2023-06-28
CN101848700A (zh) 2010-09-29
EP2217205A1 (en) 2010-08-18
KR101589317B1 (ko) 2016-01-28
JP5653218B2 (ja) 2015-01-14
IL262990B1 (en) 2023-06-01
HRP20230178T3 (hr) 2023-03-31
PT2295035T (pt) 2016-08-22
HK1149721A1 (en) 2011-10-14
ES2587336T3 (es) 2016-10-24
RU2493844C3 (ru) 2017-07-05
US20240115536A1 (en) 2024-04-11
CA2703598C (en) 2016-08-09
SI2217205T1 (sl) 2015-10-30
DK2217205T3 (en) 2015-05-11
EP2295035A3 (en) 2012-08-08
KR101700062B1 (ko) 2017-01-26
JP2015038069A (ja) 2015-02-26
US20210085631A1 (en) 2021-03-25
KR101589317B9 (ko) 2022-11-23
HRP20150459T1 (hr) 2015-07-17
PE20091390A1 (es) 2009-10-13
NZ584686A (en) 2013-03-28
CL2008003298A1 (es) 2009-06-26
DK3067043T3 (da) 2023-02-27
HK1224195A1 (en) 2017-08-18
US20100267786A1 (en) 2010-10-21
IL262990A (en) 2018-12-31
PL3067043T3 (pl) 2023-05-08
IL205208A (en) 2017-01-31
HUE028866T2 (en) 2017-01-30
ES2939163T3 (es) 2023-04-19
IL249922A0 (en) 2017-03-30
EP2295035A2 (en) 2011-03-16
FI3067043T3 (fi) 2023-03-18
PT2217205E (pt) 2015-06-08
MY153730A (en) 2015-03-13
RU2493844C2 (ru) 2013-09-27
EP2217205B1 (en) 2015-03-04
RU2010123027A (ru) 2011-12-20
PE20141072A1 (es) 2014-09-10
IL205208A0 (en) 2010-12-30
JP2011503082A (ja) 2011-01-27
SI3067043T1 (sl) 2023-04-28
TWI484982B (zh) 2015-05-21
CA2703598A1 (en) 2009-05-14
BRPI0823505A2 (pt) 2015-06-16
TN2010000200A1 (en) 2011-11-11
MX2010004930A (es) 2010-05-27
SG185951A1 (en) 2012-12-28
CY1116280T1 (el) 2017-03-15
ECSP10010160A (es) 2010-06-29
WO2009061713A1 (en) 2009-05-14
MA31797B1 (fr) 2010-10-01
EP3067043A1 (en) 2016-09-14
AR069184A1 (es) 2010-01-06
PL2217205T3 (pl) 2015-07-31
SI2295035T1 (sl) 2016-09-30
HK1143529A1 (en) 2011-01-07
EP2295035B1 (en) 2016-05-18
KR20100085087A (ko) 2010-07-28
CY1117883T1 (el) 2017-05-17
IL262990B2 (en) 2023-10-01
AU2008324878A1 (en) 2009-05-14
DK2295035T3 (en) 2016-08-29
KR101700062B9 (ko) 2022-11-23
EP4186491A1 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
IL262990A (en) Dual-activity pharmaceutical compositions based on angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor superstructures
HUS1600025I1 (hu) Egy angiotenzin receptor antagonistát és egy NEP inhibitort tartalmazó gyógyászati kombinációk
IL194642A0 (en) Antagonist anti-cd40 antibody pharmaceutical compositions
IL197788A0 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
PL2046887T3 (pl) Kompozycje poliolefinowe ulegające sieciowaniu pod wpływem światła
IL192613A (en) Cycloalkylamines and their pharmaceutical compositions
PL2059246T3 (pl) Kompozycje terapeutyczne zawierające swoistego antagonistę receptora endoteliny i inhibitor pde5
EP2075252A4 (en) NK1 Receptor Antagonists COMPOSITION
ZA200810178B (en) Pharmaceutical compositions for sustained release of phenyephrine
EP2155160A4 (en) THIXOTROPIC PHARMACEUTICAL COMPOSITIONS
GB2450580B (en) Poly-TLR antagonist
HK1143529B (en) Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
ZA200704717B (en) Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
ITMI20062230A1 (it) Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
GB0619891D0 (en) Pharmaceutical composition of risedronate
IL178378A0 (en) Extended release pharmaceutical compositions